Afatinib (Giotrif)
Afatinib risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Giotrif.
Afatinib (brand names: Giotrif) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Oncology tyrosine kinase inhibitor with potential for fatigue and diarrhea affecting work capacity.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Oncology tyrosine kinase inhibitor with potential for fatigue and diarrhea affecting work capacity.
Regulatory and Compliance Guidance
When Afatinib appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Check this medication against your full medication list
Run a full risk assessment including Afatinib interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.